tetano
Editor, Senior Moderator
Clin Chem Lab Med
. 2021 Feb 19.
doi: 10.1515/cclm-2020-1801. Online ahead of print.
A low level of CD16 [SUP]pos[/SUP] monocytes in SARS-CoV-2 infected patients is a marker of severity
Marc Vasse[SUP] 1 2 [/SUP], Benjamin Zuber[SUP] 3 [/SUP], Laurie Goubeau[SUP] 1 [/SUP], Marie-Christine Ballester[SUP] 4 [/SUP], Mathilde Roumier[SUP] 5 [/SUP], Fr?d?rique Delcominette[SUP] 1 [/SUP], Florence Habarou[SUP] 1 [/SUP], Emilie Jolly[SUP] 1 [/SUP], Felix Ackermann[SUP] 5 [/SUP], Charles Cerf[SUP] 3 [/SUP], Eric Farfour[SUP] 1 [/SUP], Tiffany Pascreau[SUP] 1 2 [/SUP], SARS-CoV-2 Foch Hospital Study Group
Affiliations
Abstract
Objectives: Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14[SUP]pos[/SUP]CD16[SUP]neg[/SUP]), non-classical (CD14[SUP]dim[/SUP]CD16[SUP]pos[/SUP]), and intermediate (CD14[SUP]pos[/SUP]CD16[SUP]pos[/SUP]) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16[SUP]neg[/SUP]) and CD16[SUP]pos[/SUP] monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.
Methods: We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16[SUP]neg[/SUP] and CD16[SUP]pos[/SUP] monocytes.
Results: In the entire population, median CD16[SUP]neg[/SUP] and CD16[SUP]pos[/SUP] monocyte levels (0.398 and 0.054 ? 10[SUP]9[/SUP]/L, respectively) were in the normal range [(0.3-0.7 ? 10[SUP]9[/SUP]/L) and (0.015-0.065 ? 10[SUP]9[/SUP]/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16[SUP]pos[/SUP] monocyte count (0.018 ? 10[SUP]9[/SUP]/L) in comparison to the 70 patients who were discharged (0.064 ? 10[SUP]9[/SUP]/L) or were hospitalized in conventional units (0.058 ? 10[SUP]9[/SUP]/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16[SUP]pos[/SUP] monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).
Conclusions: Quantification of CD16[SUP]pos[/SUP] monocytes and the ratio [absolute neutrophil count/CD16[SUP]pos[/SUP] monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.
Keywords: CD16posmonocytes; COVID-19; intensive care unit.
. 2021 Feb 19.
doi: 10.1515/cclm-2020-1801. Online ahead of print.
A low level of CD16 [SUP]pos[/SUP] monocytes in SARS-CoV-2 infected patients is a marker of severity
Marc Vasse[SUP] 1 2 [/SUP], Benjamin Zuber[SUP] 3 [/SUP], Laurie Goubeau[SUP] 1 [/SUP], Marie-Christine Ballester[SUP] 4 [/SUP], Mathilde Roumier[SUP] 5 [/SUP], Fr?d?rique Delcominette[SUP] 1 [/SUP], Florence Habarou[SUP] 1 [/SUP], Emilie Jolly[SUP] 1 [/SUP], Felix Ackermann[SUP] 5 [/SUP], Charles Cerf[SUP] 3 [/SUP], Eric Farfour[SUP] 1 [/SUP], Tiffany Pascreau[SUP] 1 2 [/SUP], SARS-CoV-2 Foch Hospital Study Group
Affiliations
- PMID: 33606928
- DOI: 10.1515/cclm-2020-1801
Abstract
Objectives: Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14[SUP]pos[/SUP]CD16[SUP]neg[/SUP]), non-classical (CD14[SUP]dim[/SUP]CD16[SUP]pos[/SUP]), and intermediate (CD14[SUP]pos[/SUP]CD16[SUP]pos[/SUP]) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16[SUP]neg[/SUP]) and CD16[SUP]pos[/SUP] monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.
Methods: We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16[SUP]neg[/SUP] and CD16[SUP]pos[/SUP] monocytes.
Results: In the entire population, median CD16[SUP]neg[/SUP] and CD16[SUP]pos[/SUP] monocyte levels (0.398 and 0.054 ? 10[SUP]9[/SUP]/L, respectively) were in the normal range [(0.3-0.7 ? 10[SUP]9[/SUP]/L) and (0.015-0.065 ? 10[SUP]9[/SUP]/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16[SUP]pos[/SUP] monocyte count (0.018 ? 10[SUP]9[/SUP]/L) in comparison to the 70 patients who were discharged (0.064 ? 10[SUP]9[/SUP]/L) or were hospitalized in conventional units (0.058 ? 10[SUP]9[/SUP]/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16[SUP]pos[/SUP] monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).
Conclusions: Quantification of CD16[SUP]pos[/SUP] monocytes and the ratio [absolute neutrophil count/CD16[SUP]pos[/SUP] monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.
Keywords: CD16posmonocytes; COVID-19; intensive care unit.